TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31515154

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus carboplatin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 160
Study: 28507057

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus Simvastatin
Number of subjects: 18015

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 18015
Study: 25415292

Group type: EXPERIMENTAL
Intervention: 4-drug regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-drug arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-drug regimen vs 3-drug arm
Number of subjects: 0
Study: 23922746

Group type: EXPERIMENTAL
Intervention: L-arginine (12 g over 8 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 20671070

Group type: EXPERIMENTAL
Intervention: Bracket removal (T2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 months post-treatment (T3)
Number of subjects: 24
Study: 19439881

Group type: EXPERIMENTAL
Intervention: 1% clindamycin lotion (C lotion) twice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1% clindamycin+0.025% tretinoin lotion once nightly (CT lotion)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1% clindamycin+2% salicylic acid lotion twice daily (CS lotion)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of all treatments
Number of subjects: 42
Study: 16603564

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone autografts
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Hamstring autografts
Number of subjects: 1512
Study: 15656050

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (weight loss and positional therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandibular advancement techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP (standard therapy)
Number of subjects: 0
Study: 11379377

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low-dose oral estrogen (estriol 2 mg daily)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Unopposed transdermal estrogen (estradiol 50 micrograms/24 h)
Number of subjects: 158
Study: 9519490

Group type: EXPERIMENTAL
Intervention: 3-month traditional therapeutic community program
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: 6-month traditional therapeutic community program
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: 3-month modified therapeutic community program emphasizing relapse prevention and health education
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: 6-month modified therapeutic community program emphasizing relapse prevention and health education
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: 12-month program for those who stayed at least 171 days
Number of subjects: 628

Group type: COMPARATOR
Intervention: Shorter programs (3-month) for those who dropped out early
Number of subjects: 628
Study: 8454106

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Year 1 IGT subjects
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Baseline variables (FPG and 2-h plasma glucose)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Year 1 baseline (90-min plasma glucose)
Number of subjects: 113
Study: 3683485

Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy (doxorubicin combined with cyclophosphamide or cyclophosphamide combined with methotrexate, fluorouracil, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent chemotherapy (stopped after three cycles, repeated only with disease progression)
Number of subjects: 0
Study: 29258028

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based Cognitive Behavioral Therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 28409397

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PIST (Prolonged Intermittent Sprint Training)
Number of subjects: 55

Group type: COMPARATOR
Intervention: HIIT
Number of subjects: 55

Group type: COMPARATOR
Intervention: CTRL (Sedentary Control Group)
Number of subjects: 55
Study: 23852077

Group type: EXPERIMENTAL
Intervention: Transdermal diclofenac patches
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 40
Study: 23294179

Group type: EXPERIMENTAL
Intervention: Combination regimen of glucosamine and low-dose cyclosporin A (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single regimen of low-dose cyclosporin A (S)
Number of subjects: 12
Study: 21924715

Group type: EXPERIMENTAL
Intervention: Inguinal varicocelectomy with ligation of both internal and external spermatic veins
Number of subjects: 74

Group type: COMPARATOR
Intervention: Retroperitoneal varicocelectomy (ligation of internal spermatic vein)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 74
Study: 17096678

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg, single subcutaneous or intramuscular injection)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Degarelix (120-320 mg, multiple subcutaneous doses)
Number of subjects: 228
Study: 15366325

Group type: EXPERIMENTAL
Intervention: Deramciclane 60 mg b.i.d. for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11451623

Group type: EXPERIMENTAL
Intervention: 60 mg/day raloxifene
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 120 mg/day raloxifene
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 390
Study: 9530841

Group type: EXPERIMENTAL
Intervention: Lexical activation during prerecognition processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spoken word recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preregognition lexical processing
Number of subjects: 0
Study: 8052956

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) 50 micrograms/24h
Number of subjects: 23
Study: 2929976

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31590390

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ischemic compression technique (ICT)
Number of subjects: 34
Study: 30078280

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.01 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 100
Study: 27082036

Group type: EXPERIMENTAL
Intervention: Multi-component influenza and Tdap vaccine promotion package
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study: 24119385

Group type: EXPERIMENTAL
Intervention: Rotator interval approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 100
Study: 21659896

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Asymptomatic tendons
Number of subjects: 20
Study: 20190833

Group type: EXPERIMENTAL
Intervention: Anti-CD13 Abs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soluble CD13
Number of subjects: 0
Study: 17279853

Group type: EXPERIMENTAL
Intervention: Values of high perceived cultural importance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Values of high actual self-importance
Number of subjects: 0
Study: 16571709

Group type: EXPERIMENTAL
Intervention: Antismoking ads focusing on young victims suffering from serious tobacco-related diseases
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Counterindustry and industry ads
Number of subjects: 1725
Study: 14675952

Group type: EXPERIMENTAL
Intervention: Surgical access therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic administration of metronidazole as an adjunct to mechanical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical treatment
Number of subjects: 0
Study: 10527711

Group type: EXPERIMENTAL
Intervention: 7 ml liquid cartilage extract
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 21 ml liquid cartilage extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8968711

Group type: EXPERIMENTAL
Intervention: Organized presentation condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unorganized presentation condition
Number of subjects: 0
Study: 1677063

Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg per day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 33
Study: 6223289

Group type: EXPERIMENTAL
Intervention: Combination of 200 micrograms fenoterol hydrobromide and 80 micrograms ipratropium bromide
Number of subjects: 9

Group type: COMPARATOR
Intervention: 400 micrograms fenoterol + placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: 200 micrograms fenoterol + placebo
Number of subjects: 9
Study: 30826256

Group type: EXPERIMENTAL
Intervention: mHealth application (MyFitnessPal©)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (standard post-operative monitoring)
Number of subjects: 56
Study: 29018100

Group type: EXPERIMENTAL
Intervention: Blood volume-guided ultrafiltration biofeedback
Number of subjects: 35

Group type: COMPARATOR
Intervention: Best clinical practice hemodialysis (control)
Number of subjects: 35
Study: 26787637

Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI)
Number of subjects: 18
Study: 24817188

Group type: COMPARATOR
Intervention: Continuous theta-burst stimulation (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of continuous and intermittent theta-burst stimulation (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham theta-burst stimulation (Group D)
Number of subjects: 60
Study: 23010558

Group type: EXPERIMENTAL
Intervention: AZD6370 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD6370 60 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD6370 180 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD6370 (180 mg total dose in one, two or four divided doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19281330

Group type: EXPERIMENTAL
Intervention: 2 doses of 15 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Number of subjects: 402

Group type: COMPARATOR
Intervention: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine (14 days apart)
Number of subjects: 402
Study: 17616777

Group type: EXPERIMENTAL
Intervention: PPARG Pro12Ala variant
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: PPARG T1431 allele
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ADRB3 Trp64Arg variant
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ADRB3 Arg64 allele
Number of subjects: 84
Study: 15976780

Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 10500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10500
Study: 12471297

Group type: EXPERIMENTAL
Intervention: LSE+high‐intensity PT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LSE+PT (combined moderate and high-intensity PT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LSE-alone
Number of subjects: 80
Study: 10450538

Group type: EXPERIMENTAL
Intervention: 300 mg dihydroartemisinin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 300 mg dihydroartemisinin with 750 mg mefloquine
Number of subjects: 10
Study: 7761739

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg) added to decaffeinated coffee at 2220 and 0120 hours for the first 3 nights.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (given on nights 4 and 5).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caffeine and Placebo (both groups received placebo on nights 4 and 5).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caffeine and Placebo (during the SALT task).
Number of subjects: 30
Study: 2143266

Group type: EXPERIMENTAL
Intervention: Loratadine (5 mg daily; 2.5 mg for children under 20 kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dexchlorpheniramine (1 mg every 8 hours; 0.5 mg for the youngest children)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall clinical assessment for both drugs
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Loratadine and dexchlorpheniramine
Number of subjects: 31
Study: 7262454

Group type: EXPERIMENTAL
Intervention: pHresh 3.5
Number of subjects: 0
Study: 31999300

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 394

Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg intravitreous injections)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Ranibizumab (after censoring VF results after PRP treatments)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Laser treatment (initial PRP session)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Laser treatment (additional PRP sessions)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Laser treatment (endolaser)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Ranibizumab injections
Number of subjects: 394
Study: 30172451

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg daily for 12 weeks
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg daily for 4 weeks + 50 mg daily for 8 weeks
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg for 4 weeks followed by 50 mg for 8 weeks
Number of subjects: 242
Study: 27487526

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26362051

Group type: EXPERIMENTAL
Intervention: Trabecular Metal™ (TM) spacers as standalone (SA) devices
Number of subjects: 80

Group type: COMPARATOR
Intervention: Trabecular Metal™ (TM) spacers with pedicle screw fixation (PF)
Number of subjects: 80
Study: 23954724

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 94
Study: 21907317

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2314
Study: 18466654

Group type: EXPERIMENTAL
Intervention: High GI and high GL (H-H)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low GI and low GL (L-L)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High GI and low GL (H-L)
Number of subjects: 8
Study: 17157112

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 14563793

Group type: EXPERIMENTAL
Intervention: Nonstretchable silk tape
Number of subjects: 99

Group type: COMPARATOR
Intervention: Perforated cloth tape
Number of subjects: 99
Study: 10998876

Group type: EXPERIMENTAL
Intervention: PCEA using a disposable PCA device (3.0 ml type)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Continuous epidural group with epidural fentanyl (15 micrograms.ml‐1) and bupivacaine (1.25 mg.ml‐1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 8698952

Group type: EXPERIMENTAL
Intervention: 8-session cognitive-behavioral therapy (CB)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 16-session cognitive-behavioral therapy (CB)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 8-session psychodynamic-interpersonal therapy (PI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 16-session psychodynamic-interpersonal therapy (PI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: psychodynamic-interpersonal therapy (PI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: cognitive-behavioral therapy (CB)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 8-session treatments
Number of subjects: 117

Group type: COMPARATOR
Intervention: 16-session treatments
Number of subjects: 117
Study: 1427127

Group type: EXPERIMENTAL
Intervention: Vitamin-D-fortified liquid milk
Number of subjects: 98

Group type: COMPARATOR
Intervention: Unsupplemented milk
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 98
Study: 3892663

Group type: EXPERIMENTAL
Intervention: Padma 28
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31010876

Group type: EXPERIMENTAL
Intervention: Unrecognized myocardial infarction (MI) detected by delayed‐enhancement MRI (DE‐MRI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Presence of unrecognized MI by DE‐MRI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unrecognized MI by DE‐MRI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Addition of unrecognized MI to clinical indices
Number of subjects: 120
Study: 29897564

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU/d)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 26890560

Group type: EXPERIMENTAL
Intervention: Medicaid early support (n = 9)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Medicaid late support (n = 9)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-Medicaid early support (n = 11)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-Medicaid late support (n = 10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Groups with early support
Number of subjects: 39
Study: 24071376

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 46
Study: 22155435

Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) up-titration
Number of subjects: 219
Study: 20422396

Group type: EXPERIMENTAL
Intervention: Antidepressant medicines (ADMs) use
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Baseline depression symptoms (BDI scores ≥ 11)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Both depression markers (elevated symptom scores and ADMs use)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Continuous BDI scores
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: ADM use
Number of subjects: 5145
Study: 17926164

Group type: EXPERIMENTAL
Intervention: Evidence-informed protocol to protect and prevent body image concerns
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Body image protection protocol
Number of subjects: 23
Study: 16940738

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 mug
Number of subjects: 355

Group type: COMPARATOR
Intervention: Intramuscular syntometrine
Number of subjects: 355
Study: 15491319

Group type: COMPARATOR
Intervention: Control protocol: rinsed twice daily for 1 min with 0.1% chlorhexidine (CHX) for 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test protocol: applied CHX locally using a very soft surgical toothbrush from days 3 to 14, and a soft toothbrush from days 14 to 28, twice daily, in addition to CHX rinsing.
Number of subjects: 60
Study: 11307266

Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration for 10 min (Groups 4, 5, 6)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No ultrasonic vibration (Groups 1, 2, 3)
Number of subjects: 84
Study: 14655831

Group type: EXPERIMENTAL
Intervention: Citalopram at a starting dose of 20 mg for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 32
Study: 8306595

Group type: EXPERIMENTAL
Intervention: Self-titrating insulin regimen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-mixed insulin (30:70) delivered by disposable pen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin ratios other than 30:70
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuation on the pen for a further 12 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preference for disposable pen and pre-mixed insulin regimen
Number of subjects: 40
Study: 3525572

Group type: EXPERIMENTAL
Intervention: Wide pneumatic tourniquet (12.5 cm) at low pressure
Number of subjects: 750

Group type: COMPARATOR
Intervention: Conventional tourniquet (9 cm) at higher pressures
Number of subjects: 750
Study: 30589994

Group type: EXPERIMENTAL
Intervention: ACT-774312 50 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACT-774312 (single doses of 1-1000 mg or multiple doses of 30-500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-774312
Number of subjects: 0
Study: 29522079

Group type: EXPERIMENTAL
Intervention: Treatment-as-prevention intervention including monthly testing for HIV and rapid treatment initiation for those who became HIV-positive.
Number of subjects: 3337

Group type: EXPERIMENTAL
Intervention: Monthly testing for HIV among HIV-negative individuals.
Number of subjects: 3337

Group type: EXPERIMENTAL
Intervention: Linking participants to health care after the study.
Number of subjects: 3337
Study: 26794930

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day; 6-week cycles of 4 weeks on, 2 weeks off)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 108
Study: 24178792

Group type: EXPERIMENTAL
Intervention: Anatabine (9-24 mg/d), administered orally 3 times a day for 3 months
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo, administered orally 3 times a day for 3 months
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Anatabine
Number of subjects: 146